首个原型检查点抑制剂 B 细胞表位疫苗（PD1-Vaxx）正在运往澳大利亚和美国进行人体 1 期临床试验：利用未来新型协同疫苗组合。
First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations.
机构信息
Department of Obstetrics and Gynecology, Division of Vaccine Research, The Ohio State Wexner Medical Center, Columbus, OH, USA.
Arthur G. James Cancer Hospital & Solove Research, Comprehensive Cancer Center, Columbus, OH, USA.
出版信息
Br J Cancer. 2021 Jul;125(2):152-154. doi: 10.1038/s41416-021-01342-9. Epub 2021 Mar 26.
Abstract
We developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) to rival nivolumab therapy which has received ethics approvals for a Phase 1 clinical trial in Australia. The US FDA granted Investigational New Drug approval to Imugene Ltd for clinical testing in NSCLC. We demonstrated synergistic vaccine combinations with an HER-2 targeted vaccine (B-Vaxx).
摘要
我们开发了一种 PD-1 B 细胞表位疫苗（PD1-Vaxx），以与已获得澳大利亚 1 期临床试验伦理批准的纳武单抗治疗相媲美。美国 FDA 授予 Imugene 公司在 NSCLC 中进行临床测试的新药研究批准。我们证明了与 HER-2 靶向疫苗（B-Vaxx）的协同疫苗组合。
相似文献
1
First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations.首个原型检查点抑制剂 B 细胞表位疫苗（PD1-Vaxx）正在运往澳大利亚和美国进行人体 1 期临床试验：利用未来新型协同疫苗组合。
Br J Cancer. 2021 Jul;125(2):152-154. doi: 10.1038/s41416-021-01342-9. Epub 2021 Mar 26.
2
Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model.一种新型人PD-1 B细胞疫苗（PD1-Vaxx）以及双重曲妥珠单抗/帕妥珠单抗样HER-2 B细胞表位疫苗（B-Vaxx）联合免疫疗法在同基因小鼠模型中的免疫原性和抗肿瘤疗效
Oncoimmunology. 2020 Oct 1;9(1):1818437. doi: 10.1080/2162402X.2020.1818437.
3
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).一种新发现的 PD-L1 B 细胞表位肽疫苗（PDL1-Vaxx）在多种同基因小鼠模型中表现出强大的免疫反应和有效的抗肿瘤免疫作用，并与双 HER-2 B 细胞疫苗（B-Vaxx）具有协同作用。
Oncoimmunology. 2022 Oct 5;11(1):2127691. doi: 10.1080/2162402X.2022.2127691. eCollection 2022.
4
Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys).一种新型人源PD-1 B细胞肽癌症疫苗PD1-Vaxx从BALB/c小鼠到比格犬及非人类灵长类动物（食蟹猴）的临床前研究
Front Oncol. 2022 May 13;12:826566. doi: 10.3389/fonc.2022.826566. eCollection 2022.
5
A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.通过免疫检查点抑制剂模拟表位的主动免疫实现基于 B 细胞的癌症疫苗的新策略。
Front Immunol. 2020 May 27;11:895. doi: 10.3389/fimmu.2020.00895. eCollection 2020.
6
Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.黑色素瘤疫苗——AVAX科技公司：DNP-VACC、M-Vax。
BioDrugs. 2003;17(1):69-72. doi: 10.2165/00063030-200317010-00007.
7
Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.流感病毒减毒活疫苗鼻内接种——MedImmune疫苗：CAIV-T，流感病毒减毒活疫苗鼻内接种。
Drugs R D. 2003;4(5):312-9. doi: 10.2165/00126839-200304050-00007.
8
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).术前 PD1 检查点阻断和核因子κB 受体激活剂配体（RANKL）抑制在非小细胞肺癌（NSCLC）中的药效学：一项多中心、开放标签、1B/2 期、转化试验（POPCORN）的研究方案。
Trials. 2019 Dec 19;20(1):753. doi: 10.1186/s13063-019-3951-x.
9
In Silico Approach in Designing a Novel Multi-Epitope Vaccine Candidate against Non-Small Cell Lung Cancer with Overexpressed G Protein-Coupled Receptor 56.基于表达异常的 G 蛋白偶联受体 56 的非小细胞肺癌新型多表位疫苗设计的计算方法。
Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2297-2306. doi: 10.31557/APJCP.2020.21.8.2297.
10
Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001.在 HER2/neu 过表达的晚期胃癌患者中 B 细胞表位疫苗的临床和免疫反应-来自 IMU.ACS.001 期试验的结果。
Clin Cancer Res. 2021 Jul 1;27(13):3649-3660. doi: 10.1158/1078-0432.CCR-20-3742. Epub 2021 Apr 20.
引用本文的文献
1
The next generation of immunotherapies for lung cancers.肺癌的下一代免疫疗法。
Nat Rev Clin Oncol. 2025 Jun 17. doi: 10.1038/s41571-025-01035-9.
2
Novel Chimeric CTLA-4 B-cell Epitope Peptide Vaccines Demonstrate Effective Antitumor Immunity with/without PD1/PDL1 Blockade in Multiple Syngeneic Murine Models of Breast and Colorectal Cancers.新型嵌合CTLA-4 B细胞表位肽疫苗在多种乳腺癌和结直肠癌同基因小鼠模型中，无论有无PD1/PDL1阻断，均表现出有效的抗肿瘤免疫。
Mol Cancer Ther. 2025 Sep 2;24(9):1362-1377. doi: 10.1158/1535-7163.MCT-24-0908.
3
Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.联合接种靶向Her-2/neu的B细胞肽和免疫检查点作为癌症治疗的新选择
Cancers (Basel). 2022 Nov 18;14(22):5678. doi: 10.3390/cancers14225678.
4
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx).一种新发现的 PD-L1 B 细胞表位肽疫苗（PDL1-Vaxx）在多种同基因小鼠模型中表现出强大的免疫反应和有效的抗肿瘤免疫作用，并与双 HER-2 B 细胞疫苗（B-Vaxx）具有协同作用。
Oncoimmunology. 2022 Oct 5;11(1):2127691. doi: 10.1080/2162402X.2022.2127691. eCollection 2022.
5
Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics.利用癌症疫苗激发免疫系统：从预防到治疗
Vaccines (Basel). 2022 May 21;10(5):816. doi: 10.3390/vaccines10050816.
本文引用的文献
1
B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine.B 细胞表位肽癌症疫苗：与新型检查点肽疫苗联合免疫疗法的新范例。
Future Oncol. 2020 Aug;16(23):1767-1791. doi: 10.2217/fon-2020-0224. Epub 2020 Jun 21.
Zotero 插件